ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 57 filers reported holding ONCOCYTE CORP in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $10,281 | -31.6% | 44,700 | +5.4% | 0.00% | – |
| Q1 2023 | $15,027 | +7.3% | 42,400 | -1.2% | 0.00% | – |
| Q4 2022 | $14,000 | -58.8% | 42,900 | -6.5% | 0.00% | – |
| Q3 2022 | $34,000 | +183.3% | 45,900 | +232.6% | 0.00% | – |
| Q2 2022 | $12,000 | -42.9% | 13,800 | -0.9% | 0.00% | – |
| Q1 2022 | $21,000 | -30.0% | 13,930 | +1.9% | 0.00% | – |
| Q4 2021 | $30,000 | -38.8% | 13,670 | -0.7% | 0.00% | – |
| Q3 2021 | $49,000 | -70.1% | 13,770 | -79.9% | 0.00% | – |
| Q4 2020 | $164,000 | +70.8% | 68,470 | -0.7% | 0.00% | – |
| Q3 2020 | $96,000 | -26.7% | 68,975 | +0.6% | 0.00% | – |
| Q2 2020 | $131,000 | -23.8% | 68,580 | -2.1% | 0.00% | – |
| Q1 2020 | $172,000 | +11.7% | 70,080 | +2.3% | 0.00% | – |
| Q4 2019 | $154,000 | +6.2% | 68,510 | -0.4% | 0.00% | – |
| Q3 2019 | $145,000 | -13.7% | 68,810 | +2.2% | 0.00% | – |
| Q2 2019 | $168,000 | -36.8% | 67,300 | 0.0% | 0.00% | – |
| Q1 2019 | $266,000 | – | 67,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 17,349,945 | $25,851,000 | 1.86% |
| Defender Capital, LLC. | 2,562,130 | $4,001,000 | 1.39% |
| PURA VIDA INVESTMENTS, LLC | 12,223,953 | $18,214,000 | 0.59% |
| Penbrook Management LLC | 578,150 | $861,000 | 0.56% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $492,000 | 0.52% |
| Orbimed Advisors | 3,493,800 | $5,206,000 | 0.08% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $112,000 | 0.07% |
| Fort Sheridan Advisors LLC | 135,000 | $201,000 | 0.06% |
| AWM Investment Company, Inc. | 241,867 | $360,000 | 0.05% |
| WEALTH EFFECTS LLC | 49,000 | $73,000 | 0.03% |